Global Endometrial Cancer Epidemiology Forecast to 2030 – Understanding the Trends Shaping and Driving the Market – ResearchAndMarkets.com | Financial Buzz

Global Endometrial Cancer Epidemiology Forecast to 2030 – Understanding the Trends Shaping and Driving the Market – ResearchAndMarkets.com

The “Endometrial Cancer – Epidemiology Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering.

Endometrial cancer is the most common form of uterine cancer, arising from the endometrial lining of the uterus. Endometrioid endometrial cancer is highly associated with increased estrogen levels, making it more common among young women, women with higher levels of body fat, and in those taking a form of exogenous estrogen.

In the 8MM, the diagnosed incident cases of endometrial cancer are expected to increase from 120,883 cases in 2020 to 133,690 cases in 2030, at an Annual Growth Rate (AGR) of 1.06%. In the five major European markets (EU5: France, Germany, Italy, Spain, and the UK), the diagnosed incident cases of endometrial cancer are expected to increase from 42,775 cases in 2020 to 47,947 cases in 2030, at an AGR of 1.21%.

When examining the AGR by individual market, The publisher forecasts that all markets will see an increase in the diagnosed incident cases of endometrial cancer during the forecast period. As seen in Figure 2, in 2020, there were 483,737 five-year diagnosed prevalent cases of endometrial cancer in the 8MM, which is expected to increase to 547,783 cases by 2030, at an AGR of 1.32%.

Scope

  • The Endometrial Cancer Epidemiology Report provides an overview of the risk factors and global trends of endometrial cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada)
  • It also includes a 10-year epidemiology forecast of the diagnosed incident and five-year diagnosed prevalent cases of endometrial cancer in these markets from 2020-2030. The incident cases are further segmented by age, International Federation of Gynecology and Obstetrics (FIGO) stage at diagnosis (I, II, IIIA, and IV), subtype (endometrioid, clear cell, serous, carcinosarcoma, and other), and associated biomarkers: microsatellite instability (MSI) high, mismatch repair deficiency (MMR-D), polymerase e (POLE ) ultra mutation, MSI hypermutated, copy number low (CN low), copy number high (CN high), programmed death-ligand 1 (PDL-1), and human epidermal growth factor receptor 2 (HER-2) positivity
  • The endometrial cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM

Reasons to Buy this Report

  • Develop business strategies by understanding the trends shaping and driving the global endometrial cancer market
  • Quantify patient populations in the global endometrial cancer market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for endometrial cancer therapeutics in each of the markets covered
  • Understand magnitude of endometrial cancer population by stage at diagnosis, subtypes, and mutations.

Key Topics Covered:

1. Endometrial Cancer: Executive Summary

2. Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of Endometrial Cancer

2.4.4 Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage at Diagnosis

2.4.5 Diagnosed Incident Cases of Endometrial Cancer by Subtype

2.4.6 Diagnosed Incident Cases of Endometrial Cancer by Associated Biomarker

2.4.7 Five-Year Diagnosed Prevalent Cases of Endometrial Cancer

2.5 Epidemiological Forecast for Endometrial Cancer (2020-2030)

2.5.1 Diagnosed Incident Cases of Endometrial Cancer

2.5.2 Age-Specific Diagnosed Incident Cases of Endometrial Cancer

2.5.3 Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage

2.5.4 Diagnosed Incident Cases of Endometrial Cancer by Subtype

2.5.5 Diagnosed Incident Cases of Endometrial Cancer with Associated Biomarkers

2.5.6 Diagnosed Incident Cases of Endometrial Cancer with HER2 Positivity by FIGO Stage

2.5.7 Five-Year Diagnosed Prevalent Cases of Endometrial Cancer

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/pd7qkx

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!